

## **Summary of the risk management plan for Hycamtin (topotecan)**

This is a summary of the risk management plan (RMP) for Hycamtin. Currently there are no important identified, potential risks, and missing information for Hycamtin.

Hycamtin 's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Hycamtin should be used.

This summary of the RMP for Hycamtin should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Hycamtin's RMP.

### **I. The medicine and what it is used for**

Hycamtin is authorized for relapsed small cell lung cancer (see SmPC for the full indication). It contains topotecan hydrochloride as the active substance and it is given by oral administration.

Further information about the evaluation of Hycamtin's benefits can be found in Hycamtin's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage:

<https://www.ema.europa.eu/en/medicines/human/EPAR/hycamtin>

### **II. Risks associated with the medicine and activities to minimize or further characterize the risks**

Important risks of Hycamtin, together with measures to minimize such risks and the proposed studies for learning more about Hycamtin's risks, are outlined below.

Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorized pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimize its risks.

Together, these measures constitute routine risk minimization measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analyzed, including PSUR assessment (if applicable) so

that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

## **II.A: List of important risks and missing information**

Important risks of Hycamtin are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Hycamtin. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

<b>List of important risks and missing information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

## **II.B: Summary of important risks**

Not applicable

## **II.C: Post-authorization development plan**

### **II.C.1. Studies which are conditions of the marketing authorization**

There are no studies which are conditions of the marketing authorization or specific obligation of Hycamtin.

### **II.C.2. Other studies in post-authorization development plan**

There are no studies required for Hycamtin.